High prevalence of human anti-mouse antibodies in the serum of colorectal cancer patients

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4353-4356

  Goto, Maki ^a   Kuribayashi, Kageaki ^a,b   Umemori, Yoshifumi ^a   Ohe, Yui ^a   Asanuma, Koichi ^a   Tanaka, Maki ^a,b   Kobayashi, Daisuke ^a,b   Watanabe, Naoki ^a,b  

^a SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse events; Colorectal cancer; Human anti mouse antibody (HAMA); Monoclonal antibody therapeutics; Prevalence

Indexed keywords

CANCER ANTIBODY; HUMAN MOUSE ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; MALE; PHYSICIAN; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASM STAGING;

EID: 78650229520     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kricka LJ: Human anti-animal antibody interferences in immunological assays. Clin Chem 45: 942-956, 1999.
2. Nussbaum S and Roth HJ: Human anti-mouse antibodies: pitfalls in tumor marker measurement and strategies for enhanced assay robustness; including results with Elecsys CEA. Anticancer Res 20: 5249-5252, 2000.
3. Klee GG: Human anti-mouse antibodies. Arch Pathol Lab Med 124: 921-923, 2000.
4. Shankar G, Pendley C and Stein KE: A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25: 555-561, 2007.
5. Presta LG: Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58: 640-656, 2006.
6. Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM and DeNardo SJ: Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother 55: 1451-1458, 2006.
7. Gruber R, van Haarlem LJ, Warnaar SO, Holz E and Riethmuller G: The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody C017-1A. Cancer Res 60: 1921-1926, 2000.
8. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ and Vose JM: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19: 3918-3928, 2001.
9. Schroff RW, Foon KA, Beatty SM, Oldham RK and Morgan AC Jr.: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45: 879-885, 1985.
10. Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI and Canevari S: Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 84: 62-68, 1999.
11. Koshida S, Asanuma K, Kuribayashi K, Goto M, Tsuji N, Kobayashi D, Tanaka M and Watanabe N: Prevalence of human anti-mouse antibodies (HAMAs) in routine examinations. Clin Chim Acta 411: 391-394, 2010.
12. Adams GP and Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157, 2005.
13. Stern M and Herrmann R: Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54: 11-29, 2005.
14. Cheung NK, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, Bonilla MA, Finn R, Yeh SJ and Larson SM: Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16: 3053-3060, 1998.
15. Weiner LM, Dhodapkar MV and Ferrone S: Monoclonal antibodies for cancer immunotherapy. Lancet 373: 1033-1040, 2009.
16. Hawkins BR, Saueracker GC, Dawkins RL, Davey MG and O'Connor KJ: Population study of heterophile antibodies. Vox Sang 39: 339-342, 1980.
17. Padova G, Briguglia G, Tita P, Munguira ME, Arpi ML and Pezzino V: Hypergonadotropinemia not associated to ovarian failure and induced by factors interfering in radioimmunoassay. Fertil Steril 55: 637-639, 1991.
18. Thorpe SJ, Turner C, Heath A, Feavers I, Vatn I, Natvig JB and Thompson KM: Clonal analysis of a human antimouse antibody (HAMA) response. Scand J Immunol 57: 85-92, 2003.
19. Darnell RB and Posner JB: Paraneoplastic syndromes involving the nervous system. N Engl J Med 349: 1543-1554, 2003.